Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s U.S. Overhaul Is Paying Off, But Work Is Not Done – CEO Kindler

Executive Summary

Pfizer's "fast-to-market" execution of Lyrica for fibromyalgia is evidence the company is already seeing the benefits of its new U.S. business structure, according to CEO Jeffrey Kindler

You may also be interested in...



Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain

After completing a comprehensive review of its research program, Pfizer is rebuilding its late-stage pipeline, with plans to initiate Phase III studies for four new molecular entities and multiple new indications for existing drugs in the next 12 months

Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain

After completing a comprehensive review of its research program, Pfizer is rebuilding its late-stage pipeline, with plans to initiate Phase III studies for four new molecular entities and multiple new indications for existing drugs in the next 12 months

Pfizer’s Lipitor Patent Claims Rejected by PTO In Initial Reexamination

Pfizer may lose patent protection for its blockbuster cholesterol drug Lipitor (atorvastatin) if the U.S. Patent and Trademark Office stands by an initial decision to reject the claims in the basic patent on the drug

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel